• In early May 2026, Pfizer reported first-quarter revenue of US$14.45 billion, up from US$13.72 billion a year earlier, while net income eased to US$2.69 billion and diluted EPS from continuing operations slipped to US$0.47, and the company reaffirmed full-year 2026 revenue guidance of US$59.50 billion to US$62.50 billion.
• At the same time, Pfizer advanced its pipeline and product portfolio with FDA approval of VEPPANU, positive Phase 3 results for ELREXFIO, and extended VYNDAMAX patent protection through 2031, all while completing a multi-year share repurchase program and filing a US$8.42 billion employee share offering shelf.
• We’ll now examine how this combination of an earnings beat, reaffirmed guidance, and new oncology approvals may influence Pfizer’s investment narrative.

AI is about to change healthcare. These 35 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Pfizer Investment Narrative Recap

To own Pfizer today, you need to believe it can replace expiring blockbuster revenues with newer drugs, particularly in oncology, while supporting its sizeable dividend. The latest quarter’s revenue beat and reaffirmed 2026 guidance support that pipeline-led story in the near term, but the looming patent cliff for key therapies remains the central risk that could outweigh short term progress if replacement products do not scale fast enough.

The most relevant update here is Pfizer’s settlement around VYNDAMAX, which extends effective U.S. patent protection to 2031. That extra exclusivity gives Pfizer more time to collect branded revenue from a leading ATTR-CM therapy, partly easing pressure from the 2027–2028 loss of exclusivity window while it works to grow newer assets such as VEPPANU and ELREXFIO.

Yet behind the reassuring guidance, investors should be aware that the timing and impact of patent expirations could still...

Pfizer's narrative projects $59.6 billion revenue and $12.8 billion earnings by 2028. This requires a 2.2% yearly revenue decline and an earnings increase of about $2.1 billion from $10.7 billion today.

Uncover how Pfizer's forecasts yield a $29.08 fair value, a 10% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already assuming Pfizer could reach about US$59.8 billion in revenue and US$11.7 billion in earnings by 2029, which is a much more upbeat view than the baseline patent cliff concerns reflected here, and Q1’s oncology progress plus VYNDAMAX exclusivity might either reinforce or challenge that outlook once fully reassessed.

Explore 23 other fair value estimates on Pfizer - why the stock might be worth over 2x more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Pfizer research is our analysis highlighting 1 key reward and 4 important warning signs that could impact your investment decision.
• Our free Pfizer research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Pfizer's overall financial health at a glance.

Contemplating Other Strategies?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.
• The latest GPUs need a type of rare earth metal called Dysprosium and there are only 33 companies in the world exploring or producing it. Find the list for free.
• Outshine the giants: these 16 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.